Conexeu Sciences Inc. (NASDAQ:CNXU) Short Interest Up 56.4% in August

Conexeu Sciences Inc. (NASDAQ:CNXU) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 202,485 shares, an increase of 56.4% from the August 15th total of 129,461 shares. Based on an average daily volume of 321,266 shares, the short-interest ratio is currently 0.6 days. Currently, 0.8% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CNXU. Weiss Ratings initiated coverage on shares of Conexeu Sciences in a research note on Monday, August 17th. They set a “sell (e-)” rating for the company. Zacks Research raised shares of Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. HC Wainwright assumed coverage on Conexeu Sciences in a report on Monday, June 22nd. They set a “buy” rating and a $20.00 price objective for the company. Finally, Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Conexeu Sciences currently has an average rating of “Hold” and an average price target of $20.00.

Conexeu Sciences Price Performance

CNXU opened at $5.13 on Thursday. The company has a market capitalization of $144.86 million and a PE ratio of -46.52. Conexeu Sciences has a twelve month low of $4.19 and a twelve month high of $18.79. The business’s 50-day moving average price is $7.76.

Conexeu Sciences (NASDAQ:CNXU) last released its earnings results on Monday, September 14th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). Sell-side analysts anticipate that Conexeu Sciences will post -0.4 EPS for the current fiscal year.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.